Actively Recruiting
Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
Led by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Updated on 2025-02-17
60
Participants Needed
1
Research Sites
101 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.
CONDITIONS
Official Title
Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with Parkinson's disease with Hoehn Yahr stage between 1 and 2.5
- Mini-Mental State Examination (MMSE) score of 24 or higher
- Age between 18 and 65 years
You will not qualify if you...
- History of essential tremor, stroke, epilepsy, or other defined neurological disorders
- Previous deep brain stimulation or brain surgery
- Abnormal liver or kidney function
- Chronic hepatitis B or HIV-1 infection
- Severe depression, schizophrenia, other psychiatric disorders, or drug dependence
- Serious physical diseases such as heart, lung, liver, kidney disease, blood disease, or malignant tumors
- Pregnant or breastfeeding women
- Allergy or contraindications to tenofovir disoproxil fumarate
- Age over 65 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guohua Zhao
Hangzhou, Zhejiang, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here